Friday, March 31, 2023
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for psychiatrists, family medicine/primary care clinicians, internists, neurologists, nurses, pharmacists, physician assistants, sleep medicine clinicians, and other members of the health care team for patients with major depressive disorder or major depressive episode and sleep complaints.
The goal of this activity is for learners to be better able to describe the incidence of psychiatric disorders after sleep complaints in adults with major depressive episode.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-014-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 02/24/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 2/24/2023
Valid for credit through: 2/24/2024
processing....
Major depressive episode (MDE) is a disabling condition affecting approximately 7% of adults, with sleep disturbance in 92%, and increased risk for medical and psychiatric comorbidities. Risk for poorer medical outcomes is greater than in the general population.
Shorter sleep duration is associated with many psychiatric disorders. The bidirectional association between MDE and sleep disturbance suggests the latter as a predictive prodromal symptom.
Sleep complaints by patients with a MDE may be a red flag signaling a higher risk for developing other psychiatric disorders, new research suggests.
Investigators studied 3-year incidence rates of psychiatric disorders in almost 3000 patients experiencing an MDE. Results showed that having a history of difficulty falling asleep, early morning awakening, and hypersomnia increased risk for incident psychiatric disorders.
“The findings of this study suggest the potential value of including insomnia and hypersomnia in clinical assessments of all psychiatric disorders,” write the investigators, led by Bénédicte Barbotin, MD, from the Département de Psychiatrie et d’Addictologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, France.
“Insomnia and hypersomnia symptoms may be prodromal transdiagnostic biomarkers and easily modifiable therapeutic targets for the prevention of psychiatric disorders,” they add.
The findings were published online December 21, 2022, in the Journal of Clinical Psychiatry.
Bidirectional Association
The researchers note that sleep disturbance is “one of the most common symptoms” associated with major depressive disorder and may be “both a consequence and a cause” of the condition.
Moreover, improving sleep disturbances for patients with MDE “tends to improve depressive symptoms and outcomes,” they add.
Although the possibility of a bidirectional association between MDE and sleep disturbances “offers a new perspective that sleep complaints might be a predictive prodromal symptom,” the association of sleep complaints with the subsequent development of other psychiatric disorders in MDE “remains poorly documented,” the investigators write.
The observation that sleep complaints are associated with psychiatric complications and adverse outcomes, such as suicidality and substance overdose, suggests that longitudinal studies “may help to better understand these relationships.”
To investigate these issues, the researchers examined 3 sleep complaints among patients with MDE: trouble falling asleep, early morning awakening, and hypersomnia. They adjusted for an array of variables, including antisocial personality disorders, use of sedatives or tranquilizers, sociodemographic characteristics, MDE severity, poverty, obesity, educational level, and stressful life events.
They also used a “bifactor latent variable approach” to “disentangle” a number of effects, including those shared by all psychiatric disorders; those specific to dimensions of psychopathology, such as internalizing dimension; and those specific to individual psychiatric disorders, such as dysthymia.
They drew on data from waves 1 and 2 of the National Epidemiological Survey on Alcohol and Related Conditions, a large, nationally representative survey conducted in 2001 to 2002 (wave 1) and 2004 to 2005 (wave 2) by the National Institute on Alcoholism and Alcohol Abuse.
The analysis included 2864 participants who experienced MDE in the year before wave 1 and who completed interviews at both waves.
The researchers assessed past-year Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), axis I disorders and baseline sleep complaints at wave 1, as well as incident DSM-IV axis I disorders between the 2 waves, including substance use, mood, and anxiety disorders.
Screening Needed?
Results showed a wide range of incidence rates for psychiatric disorders between wave 1 and wave 2, ranging from 2.7% for cannabis use to 8.2% for generalized anxiety disorder.
The lifetime prevalence of sleep complaints was higher among participants who developed a psychiatric disorder between the 2 waves than among those who did not have sleep complaints. The range (from lowest to highest percentage) is shown in the following table.
|
Sleep complaint |
Psychiatric disorder |
Percentage |
|---|---|---|
|
Difficulty falling asleep |
Cannabis use disorder |
67.6 |
|
Panic disorder |
76.4 |
|
|
Morning awakenings |
Cannabis use disorder |
43.3 |
|
Dysthymia |
55.6 |
|
|
Hypersomnia |
Nicotine use disorder |
51.3 |
|
Social anxiety disorder |
72.1 |
A higher number of sleep complaints was also associated with higher percentages of psychiatric disorders.
Hypersomnia, in particular, significantly increased the odds of having another psychiatric disorder. For patients with major depressive disorder who reported hypersomnia, the mean number of sleep disorders was significantly higher than for patients without hypersomnia (2.08 vs 1.32; P<.001).
After adjusting for sociodemographic and clinical characteristics and antisocial personality disorder, the effects shared across all sleep complaints were “significantly associated with the incident general psychopathology factor, representing mechanisms that may lead to incidence of all psychiatric disorders in the model,” they add.
The researchers note that insomnia and hypersomnia can impair cognitive function, decision-making, problem-solving, and emotion processing networks, thereby increasing the onset of psychiatric disorders in vulnerable individuals.
Shared biological determinants, such as monoamine neurotransmitters that play a major role in depression, anxiety, substance use disorders, and the regulation of sleep stages, may also underlie both sleep disturbances and psychiatric disorders, they speculate.
“These results suggest the importance of systematically assessing insomnia and hypersomnia when evaluating psychiatric disorders and considering these symptoms as non-specific prodromal or at-risk symptoms, also shared with suicidal behaviors,” the investigators write. “In addition, since most individuals who developed a psychiatric disorder had at least 1 sleep complaint, all psychiatric disorders should be carefully screened among individuals with sleep complaints,” they add.
Transdiagnostic Phenomenon
Commenting for Medscape Medical News, Roger McIntyre, MD, professor of psychiatry and pharmacology at the University of Toronto, Ontario, Canada, and head of the Mood Disorders Psychopharmacology Unit, noted that the study replicates previous observations that a bidirectional relationship exists between sleep disturbances and mental disorders and that there “seems to be a relationship between sleep disturbance and suicidality that is bidirectional.”
He added that he appreciated the fact that the investigators “took this knowledge one step further; and what they are saying is that within the syndrome of depression, it is the sleep disturbance that is predicting future problems.”
The data suggest that, “conceptually, sleep disturbance is a transdiagnostic phenomenon that may also be the nexus when multiple comorbid mental disorders occur,” he said.
“If this is the case, clinically, there is an opportunity here to prevent incident mental disorders in persons with depression and sleep disturbance, prioritizing sleep management in any patient with a mood disorder,” Dr McIntyre added.
The study received no specific funding from any funding agency, commercial, or not-for-profit sectors. The investigators’ relevant financial relationships are listed in the original article. Dr McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China and the Milken Institute; has received speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, and Atai Life Sciences; and is a CEO of Braxia Scientific Corp.
J Clin Psychiatry. Published online December 21, 2022.[1]
